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Background: Patients with psoriasis (PsO) suﬀer from a variety of symptoms. Tools are needed to assess PsO symptoms and signs
from the patient’s perspective.
Objective: To develop a patient-reported outcome (PRO) measure to assess symptoms and signs in individuals with moderate-to-
severe PsO.
Methods: Face-to-face concept elicitation interviews were conducted with 20 subjects with moderate-to-severe plaque PsO. Results
from the interviews, a literature review, and clinical input informed the development of the draft Psoriasis Symptoms and Signs Diary
(PSSD). Three waves of face-to-face cognitive interviews (n = 19) were conducted to evaluate the clarity and relevance of the PSSD.
Additional interviews (n = 5) were conducted to conﬁrm its content.
Results: The PSSD assesses severity of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 observable signs (skin dryness,
cracking, scaling, shedding or ﬂaking, redness, bleeding) using 0–10 numerical ratings. Two versions with diﬀerent recall periods (24 h
and past 7 days) were developed. PsO patients found the PSSD to be clear and relevant.
Limitations: The sample had limited racial diversity.
Conclusion: The PSSD, developed according to the Food and Drug Administration PRO Guidance, assesses severity of symptoms
and signs commonly associated with plaque PsO. Its measurement properties are currently being evaluated.http://dx.doi.org/10.1016/j.jdds.2015.07.004
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Figure 1. Development process.1. Introduction
Psoriasis (PsO) aﬀects 2–3.2% of the US adult popula-
tion, (Stern et al., 2004; Kurd and Gelfand, 2009;
Rachakonda et al., 2014) with around 20% considered to
have moderate-to-severe PsO (Van Voorhees et al., 2009).
Psoriasis has a signiﬁcant impact on health-related quality
of life (HRQoL) (de Arruda and De Moraes, 2001; Rapp
et al., 2001; Weiss et al., 2002; Gelfand et al., 2004;
Heydendael et al., 2004; Leino et al., 2014; Martinez-
Garcia et al., 2014) and poses a signiﬁcant humanistic
and economic burden for patients and society (Javitz
et al., 2002; Mustonen et al., 2014).
Evaluating symptoms, in terms of type and severity, is
crucial in patient care (Mrowietz et al., 2014) and central
to research on treatment eﬃcacy, which often relies on
measures of objective severity (versus subjective symptoms)
as primary outcomes of interest (Brodell and Preston, 2012;
Lajevardi et al., 2015; Molina-Leyva et al., 2014).
Clinically-based measures of severity (e.g., Body Surface
Area [BSA], the Psoriasis Area and Severity Index [PASI],
and the Physician’s Global Assessment [PGA]) (Berth-
Jones et al., 2006; Puzenat et al., 2010) track changes in
PsO severity from a clinician’s perspective. Patient-
reported outcome (PRO) measures (e.g., Dermatology Life
Quality Index [DLQI] (Finlay and Khan, 1994), Skindex
(Chren et al., 1996)) have been used in PsO research to
evaluate symptoms and their impact on HRQoL, but were
not developed exclusively for use in individuals with PsO.
Additionally, these PRO measures were not developed in
accordance with best practices to satisfy the requirements
for product labeling claims, as described in the US Food
and Drug Administration (FDA) guidance document for
PRO Development (U.S. Department of Health and
Human Services, Food and Drug Administration et al.,
2009). Other PRO measures are somewhat limited in their
scope and depth (Globe et al., 2009; Armstrong et al., 2012;
Sampogna et al., 2012; Lebwohl et al., 2014), while still
others are proprietary (Martin et al., 2011a, 2011b;
Lebwohl et al., 2014). For these reasons, a new PRO mea-
sure, the Psoriasis Symptoms and Signs Diary (PSSD), was
developed to assess symptoms and patient observable signs
in individuals with moderate-to-severe plaque PsO.2. Materials and methods
The steps involved in the development of the PSSD
included a literature search, concept elicitation interviews,drafting of initial items, and three waves of cognitive inter-
views to reﬁne the instructions, items, and response options
(Fig. 1).2.1. Literature review and concept elicitation interviews
A literature review was conducted to better understand
plaque PsO and identify existing PRO instruments that
could potentially be used or modiﬁed for use in future
PsO studies. No existing measure was identiﬁed that was
available and appropriate for use with plaque PsO, so the
decision was made to develop a new measure. As a ﬁrst step
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which included cognitive interviews of the DLQI among
patients with PsO, were reviewed to identify key symptoms
of PsO. Face-to-face, one-on-one concept elicitation inter-
views were then conducted with 20 subjects with moderate-
to-severe plaque PsO. These interviews, which followed a
discussion guide, were conducted to better understand
symptoms experienced by individuals with PsO and the
impact, if any, on their lives. Interviews were audiotaped
and transcribed. All transcripts were analyzed using
MAXQDA 11, a qualitative data analysis software. Each
transcript was coded by one coder, and then manually
reviewed by a second coder. Saturation was achieved when
no new concepts emerged.
Based on ﬁndings from the literature review, results
from concept elicitation interviews, and review by clinical
experts, the draft PSSD was developed. Two versions were
created, one with a recall period of 24 h (PSSD-24 h) and
one with a 7-day recall period (PSSD-7d). Both versions
assessed severity and frequency of symptoms.
2.2. Cognitive interviews of the draft instrument
The study protocol, interview guide, informed consent
and supporting documents were reviewed and approved
by Copernicus Group IRB (Cary, NC). Patients with
moderate-to-severe plaque PsO were recruited from two
US dermatology practices prior to participating in the
face-to-face cognitive interviews of the draft PSSD. All
subjects provided informed consent.
In order to determine whether the PSSD items were rel-
evant for patients with varying severities of PsO, adults
with mild (<3% BSA), moderate (3–10% BSA), and severe
(>10% BSA) PsO were included in these interviews. Eligible
subjects were required to live in the US and to be able to
speak, read, and write English suﬃciently well to partici-
pate in the interview. Subjects were excluded if they had
a dermatologic condition other than psoriasis that could
cause skin-related symptoms or other medical conditions
that could result in cognitive impairment.
Cognitive interviews sought to evaluate the content,
clarity, and relevance of the two versions of the draft
PSSD. Subjects completed the PSSD-24 h and reviewed
the PSSD-7d, and were then asked to describe what each
question meant in their own words (using a ‘‘think aloud”
approach). They were also asked to identify any items they
felt were inappropriate or irrelevant, and to suggest any
important symptoms they felt were missing. In addition,
subjects were asked questions to assess the clarity of each
item, the response options and instructions, and to com-
ment on the general format of the questionnaire.
Three waves of interviews were conducted to allow for
changes to be made iteratively. Ten interviews were
conducted in the ﬁrst wave, 4 in the second, and 5 in the
third. As necessary, the PSSD was modiﬁed after each
wave based on the information provided during the
interviews.2.3. Final interviews
After the third round of cognitive interviews was
completed, interviews with an additional 5 subjects with
moderate-to-severe plaque PsO (with or without psoriatic
arthritis) for > 6 months deﬁned by BSAP 10%,
PASI > 12, and PGA > 3 were conducted to conﬁrm the
content of the ﬁnal version for this population. These inter-
views included a concept elicitation portion to conﬁrm the
relevance of the PSSD items and a cognitive portion to ver-
ify the ﬁnal version of instructions, items, and response
options were appropriate for this population.
IRB
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3. Results
3.1. Demographic and clinical characteristics
The demographic and clinical characteristics of those
interviewed are summarized in Table 1. Ages ranged from
20 to 70 years, half of the subjects were female (50%), and
most were Caucasian (89%). The severity of PsO (based on
BSA) varied across the interview groups, with psoriatic
arthritis present in a little more than half of those for
whom it was assessed.
3.2. Item generation
Results of the literature review, a debrieﬁng study of the
DLQI previously conducted, input from dermatologists
(including Steve Feldman), and ﬁndings from the concept
elicitation interviews aided in the generation of items.
Twenty subjects in total were interviewed (Table 1). Satura-
tion of symptoms was reached by the 19th concept elicita-
tion interview, and it was decided that any symptom
Table 1
Demographic and clinical characteristics of subjects interviewed.
Initial concept elicitation
subjects (n = 20)
Cognitive interview
subjects (n = 19)
Final interview
subjects (n = 5)
Gender, N (%)
Male 13 (65) 7 (37) 2 (40)
Female 7 (35) 12 (63) 3 (60)
Age, yr (mean ± SD) 39.5 ± 13.6 44.2 ± 14.0 54.0 ± 13.0
Range: 20–67 Range: 25–63 Range: 41–70
Ethnicity, N (%)
Caucasian 17 (85) 18 (95) 4 (80)
African American 1 (5) 1 (5) 1 (20)
American Indian/Asian/Latino/Hispanic 2 (10) 0 (0) 0 (0)
Education, N (%)
High school diploma/equivalent 3 (5) 5 (26) 3 (60)
Some college – 2 (11) 1 (20)
College degree 14 (70) 10 (53) 1 (20)
Prof/advance degree 3 (15) 2 (11) 0 (0)
% body surface area (BSA) aﬀected (mean ± SD) –a 11.0 ± (7.8) 28.6 ± (11.1)
Severity of plaque-type psoriasis based on BSA, N (%)
Mild 0 (0) 5 (26) 0 (0)
Moderate 9 (45) 8 (42) 0 (0)
Severe 11 (55) 6 (32) 5 (100)
Years since psoriasis diagnosis, Mean ± SD 19.6 ± (12.6) 21.3 ± (14.7) 9.4 ± (9.2)
Psoriatic arthritis, N (%)
Yes (not collected) 9 (47) 5 (100)
No 10 (53) 0 (0)
a Collected as mild, moderate, and severe without the actual percentage.
Table 2
Frequency of symptoms mentioned.
Initial concept elicitation subjects (n = 20) Cognitive interview subjects (n = 19) Final interview subjects (n = 5)
Symptom n (%) n (%) n (%)
Itchiness 17 (85) 16 (84) 5 (100)
Soreness/pain/raw 16 (80) 14 (74) 3 (60)
Flakiness 15 (75) 11 (58) 3 (60)
Dry, scaly skin 14 (70) 13 (68) 3 (60)
Redness/discoloration 14 (70) 10 (53) 5 (100)
Hot/burning/stinging sensation 12 (60) 14 (74) 1 (20)
Cracking/bleeding 10 (50) 13 (68) 2 (40)
Joint pain 3 (15) 7 (37) 1 (20)
Skin tightness 2 (10) 16 (84) 0 (0)
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the draft version of the PSSD. These symptoms (Table 2)
included: itching (85%), soreness/pain (80%), ﬂakiness
(75%), redness (70%), dry/scaly skin (70%), hot/burning/
stinging sensation (60%), cracking/bleeding (50%), joint
pain (15%), and skin tightness (10%). Two exceptions were
made. First, although ‘‘pus” was only mentioned by one
subject (5%), it was included in the initial draft version of
the PSSD because it was deemed to be clinically important.
Second, the decision was made to not include ‘‘joint pain”
because it is a symptom associated with psoriatic arthritis,
rather than plaque PsO.
The initial PSSD included 8 clinical signs and 6
symptoms and assessed both the frequency and severity
of each item. Response options for frequency items rangedfrom ‘‘None of the time” to ‘‘All of the time” for the
PSSD-24 h and from 0 to 7 days for the PSSD-7d. In both
versions, response options for severity used an 11-point
scale ranging from 0 (absent) to 10 (worst imaginable).
Of the 14 items included, 12 had been reported during
the concept elicitation interviews (itching, dryness, crack-
ing, skin tightness, bleeding, burning, stinging, soreness,
shedding or ﬂaking, redness, discoloration, and scaling),
and two were based on the literature and/or input from
dermatologists (oozing pus, other skin pain).
3.3. Cognitive interviews
The 19 subjects included in the cognitive interviews
(Table 1) were asked to describe each symptoms and sign
Symptom or sign Representative Quotes
Itch
Dryness
Cracking
Skin Tightness
Shedding
or
flaking
Scaling
Pain/Soreness
Stinging
Bleeding
Burning
“Redness is when my skin is very irritated or when my psoriasis flared up a
great deal. It’s not flaky, it’s not shedding, it’s not doing anything of that nature.
It is just flared up and it’s red.”
“Bleeding is just the skin is punctured and you’re bleeding.”  
“Burning is more like a sunburn effect.”
“Burning that’s more like, I don’t know, it’s not as tolerable as stinging. Burning
is more painful.”
“Stinging is something you can deal with and tolerate. You know it might be
annoying, but a burn is something that hurts more.”
“Stinging comes usually from within. So burning is outside and stinging is
inside.”
“For me, the soreness is like difficulty like with anything like touching my skin.”
“Pain to me would be a greater feeling. So I guess if I cut myself or if my skin
was cracking terribly, I think it would cause a lot more pain than soreness
per se would. I could mostly (sic) likely relieve that soreness again with maybe 
some lotion or some type of lubricant.”
“I would just say you know something that causes you to scratch your skin, 
an irritating feeling constant.”
“Cracking would be almost a sore place where the skin’s come apart and it 
really hurts.”
“It’s real dry, it’s not moist.” 
“Just anything that would make it uncomfortable to move. That it just feels, 
I don’t know the word,I guess tight.”
“Tightness and if you rub it, it’s like powdery feeling.”
“Scaling is beforehand of shedding or flaking. It’s just a build-up of all the 
skin cells getting ready to fall off.”
“Flaking, layers of the skin are flaking off.”
Redness
Figure 2. Representative quotes regarding symptoms and signs.
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asked whether they experienced each of the symptoms
(Table 2).
Subjects indicated that the general instructions were
clear and made no suggestions for revisions. Interviews
were lengthy, and therefore not every question was asked
of every subject. Thirteen of 18 subjects (72%) asked felt
there were no missing symptoms or signs in the initial draft
PSSD and indicated that all of the symptoms and signs
were relevant and appropriate. Of 18 asked, 5 subjects
(28%) each suggested a single symptom they felt was miss-
ing: open sores, swelling or inﬂammation, joint swelling,
joint pain, and body or muscle aches. Six of 19 subjects(37%) identiﬁed at least one item that they felt may be inap-
propriate or irrelevant: skin tightness, shedding, oozing
pus, and discoloration were each mentioned once, while
other skin pain was mentioned by 4 subjects. All 18 sub-
jects who were asked said that it was easy to know whether
each symptom was due to PsO versus another condition.
Symptoms that are similar were frequently mentioned
together (e.g., burning and stinging), although the subjects’
descriptions of these items provided support that they are
diﬀerent concepts (e.g., ‘‘Burning is more like a sunburn
eﬀect,” ‘‘Stinging is more like a bee sting,” ‘‘. . . burning
is outside and stinging is inside”). Subjects indicated the
response options were clear and appropriate, but suggested
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symptoms be made explicitly clear, even if one had indi-
cated ‘‘none of the time” for frequency. In terms of the
recall period, 95% of subjects (18 out of 19) felt they could
accurately recall symptoms over a 24-h period, but 50% (9
out of 18) indicated that they would prefer to complete the
assessment less frequently than every day. All four of those
asked indicated that they preferred the 7-day version, but
11 of 16 (69%) who were asked thought their responses
would be more accurate when reported on a daily basis.
Based on the cognitive interviews, several key revisions
were made to the PSSD. First, the general instructions were
edited for clarity, in the form of minor wording changes
(e.g., ‘‘symptoms” revised to ‘‘skin symptoms”), and items
were re-ordered. The symptoms of ‘‘oozing pus,” ‘‘other
skin pain,” and ‘‘discoloration” were deleted because sub-
jects indicated they were inappropriate or irrelevant. Skin
tightness was retained due to its clinical importance. Fur-
ther, the project team noted that ‘‘skin discoloration” can
reﬂect a change in pigmentation after a PsO lesion heals,
or can be caused by more severe PsO-like redness. There-
fore, it was removed. ‘‘Soreness” was revised to ‘‘pain” pri-
marily to increase translatability. Finally, the concept of
frequency was omitted from the PSSD-24 h; it was deter-
mined that it was more relevant to know about the presence
or absence of symptoms for the 24-h recall period. How-
ever, the frequency items were retained in the PSSD-7d.
The ﬁnal versions (24-h and 7-day recall) of the PSSD
include 11 items assessing the severity of 5 symptoms (itch,
pain, stinging, burning, skin tightness) and 6 patient
observable signs (skin dryness, cracking, scaling, shedding
or ﬂaking, redness, bleeding) on a scale ranging from 0
(absent) to 10 (worst imaginable). The 7-day recall version
also asks about the frequency of each item using a scale
ranging from ‘‘None of the days” to ‘‘All of the days.”
3.4. Final set of interviews
During the concept elicitation portion of the ﬁnal set of
interviews (Table 1), subjects were asked to describe symp-
toms and signs they experienced as a result of their PsO on
a typical day. The most frequent symptoms and signs men-
tioned were the same as those reported by subjects in the
initial concept elicitation interviews, and were already
included in the PSSD: redness, itching, ﬂaking, pain, scal-
ing, and bleeding (Table 2). For the cognitive interview
portion, subjects found the instructions, items, recall per-
iod, and response options to be clear, relevant, and appro-
priate. The only revision was to change ‘‘pain from skin
lesions” to ‘‘pain from psoriasis lesions” to focus the
respondent on lesions speciﬁc to their psoriasis.
4. Discussion
Patients with plaque PsO suﬀer from a variety of skin-
related symptoms, as reﬂected in the initial concept elicita-
tion interviews. PSSD was developed based on an analysisof the transcripts from these initial interviews, as well as
from a review of existing literature and clinical input. Its
development was guided by recommendations outlined in
the FDA PRO Guidance, including a considerable amount
of patient input. Subsequent cognitive interviews indicated
that the PSSD was relevant, clear, and comprehensive.
Only slight modiﬁcations were made to the PSSD based
on feedback from study participants with PsO to enhance
clarity and translatability. The ﬁnal version of the PSSD
is an 11-item instrument assessing the severity of itch, dry-
ness, cracking, skin tightness, scaling (build-up of skin),
shedding or ﬂaking, redness, bleeding, burning, stinging,
and pain. The severity of each item in the PSSD is rated
on an 11-point numeric scale ranging from 0 (absent) to
10 (worst imaginable). Two versions of the PSSD were
developed, one with a 24-h recall period, preferable when
there tends to be daily variation in symptoms, and one with
a 7-day recall period that can be used for clinical research
when the use of a daily diary is not practical. In the 7-day
version, the frequency of each symptom is assessed using a
scale ranging from ‘‘None of the days” to ‘‘All of the
days.” Psychometric properties of the PSSD are currently
being studied.
The PSSD diﬀers from other existing PRO instruments
commonly used in PsO research, such as the DLQI. Unlike
the DLQI, the PSSD was developed according to the FDA
PRO Guidance, using input obtained directly from patients
with PsO. Additionally, when assessing symptoms that
tend to vary from day-to-day, a shorter recall period such
as the 24-h recall period utilized in the PSSD is preferred,
rather than a longer recall period such as the past 7 days
in the DLQI. The DLQI can be used across a variety of
dermatologic conditions, while the PSSD is PsO-speciﬁc
and therefore potentially more responsive to change. The
DLQI is scored to produce a single score that combines
items assessing symptoms and impacts, while the PSSD
includes only symptoms and patient-observable signs, and
can be reported either as individual items or potentially
as a score for symptom severity and a score for sign sever-
ity. Finally, some DLQI items combine multiple concepts
(e.g., itch, pain, stinging) into a single item, while PSSD
items contain only one concept each.
There are limitations of our research that should be
noted. The large majority of subjects interviewed were
Caucasian and all resided in the US. However, it is unlikely
that those of other ethnicities or individuals living in other
countries would report their symptoms diﬀerently. Some
patients may have diﬃculty distinguishing between pain,
burning, and stinging, but it is not plausible to aggregate
diﬀerent concepts into a single item in regulatory labeling,
nor would it be possible for a single term to account for
these 3 unique symptoms. Also, ‘‘redness of skin” may
not represent a suﬃcient description among individuals
with dark skin. Finally, although saturation was achieved
for those with moderate-to-severe PsO, there were limited
numbers of subjects within each severity group (mild,
moderate, and severe).
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back from patients who suﬀer from PsO and dermatolo-
gists who treat patients with PsO. As the landscape of
pharmacotherapy continues to change within the area of
PsO and the eﬃcacy of available treatments improves
(Schmitt et al., 2014), it will be important to have these
types of PsO-speciﬁc tools available. It is anticipated that
the PSSD will be a valuable outcome measure to evaluate
the signs and symptoms of patients with moderate-to-
severe plaque PsO.Conflict of interest
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